Commentary: The quest for the holy grail continues: Is levosimendan the best choice to support patients with cardiomyopathy requiring cardiac surgery?
J Thorac Cardiovasc Surg
.
2020 Jun;159(6):2312-2313.
doi: 10.1016/j.jtcvs.2019.06.136.
Epub 2019 Sep 21.
Authors
Francesco Onorati
1
,
Gianfranco Veraldi
2
,
Giuseppe Faggian
3
Affiliations
1
Division of Cardiac Surgery, University of Verona Medical School, Verona, Italy. Electronic address: francesco.onorati@univr.it.
2
Vascular Surgery Unit, University Hospitals in Verona, Verona, Italy.
3
Division of Cardiac Surgery, University of Verona Medical School, Verona, Italy.
PMID:
31653416
DOI:
10.1016/j.jtcvs.2019.06.136
No abstract available
Publication types
Editorial
Comment
MeSH terms
Cardiac Surgical Procedures*
Cardiomyopathies*
Heart
Humans
Simendan
Ventricular Function, Left
Substances
Simendan